Earnings Conference Call & Webcast on Thursday, October 15th,at 5:00 pm ET
Oct. 8, 2009 (Business Wire) -- Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that it will issue its third quarter 2009 financial results at 4:00 p.m. ET on Thursday, October 15th, 2009. In connection with this announcement, Cubist will host a conference call and webcast (with slides) at 5:00 p.m. ET on the same day to discuss its third quarter financial results, business activities, and financial outlook.
As always, the quarterly earnings call will be available via phone and webcast. The phone call dial-in information is listed below. To access the webcast, please log on to the Cubist website at cubist.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.
A replay of the webcast and teleconference will be available on Cubist’s website [for 30 days] beginning approximately three hours after the call.
*****************************************************************************
Your Teleconference Information:
Event Date: 10/15/2009
Event Time: 5:00 PM Eastern
Event Title: Third Quarter 2009 Earnings Call
Participant Dial-In Numbers: 877-407-8289
For more information: http://www.investorcalendar.com/IC/CEPage.asp?ID=149453
Replay / archive access is here:
(877) 660-6853 (Toll free)
(201) 612-7415 (Local / Int’l)
Acct. #: 351
Conference ID: 332096
*****************************************************************************
About Cubist
Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. In the U.S., Cubist markets CUBICIN® (daptomycin for injection), the first antibiotic in a new class of anti-infectives called lipopeptides. In July 2008, Cubist entered into an agreement with AstraZeneca to promote their established antibiotic, MERREM® I.V. (meropenem for injection) in the U.S. The Cubist product pipeline includes ecallantide, a recombinant human protein in Phase 2 clinical trials — CONSERV™-1 and CONSERV™-2 — for the reduction of blood loss during cardiac surgery, and two Phase 1 programs that address unmet medical needs, one in CDAD (Clostridium difficile-associated diarrhea) and the other in multi-drug resistant (MDR) Gram-negative infections. In addition, the Company, in collaboration with Alnylam Pharmaceuticals, Inc. (Cambridge, MA), has a pre-IND and a Phase 2 program underway in novel treatments for respiratory syncytial virus infections using Alnylam’s RNA-interference technology. Cubist is headquartered in Lexington, MA. Additional information can be found at Cubist’s web site at www.cubist.com.
Cubist and CUBICIN are registered trademarks of Cubist Pharmaceuticals, Inc.
AstraZeneca and MERREM are registered trademarks of the AstraZeneca group of companies.
